Novel adjuvant therapies for pancreatic adenocarcinoma

Tolutope Oyasiji, Wen Wee Ma

Research output: Contribution to journalReview articlepeer-review

7 Scopus citations


Contemporary adjuvant therapy for pancreatic cancer patients following surgical resection includes chemotherapy and chemoradiotherapy. However, the median survival remains approximately 20 months despite multi-modality treatment using gemcitabine or fluoropyrimidine systemic chemotherapy. Adjuvant randomized trials are currently underway to evaluate cytotoxic combinations found to be active in advanced disease including FOLFIRINOX, gemcitabine/nab-paclitaxel and gemcitabine/capecitabine. Immunotherapy using genetically engineered cell-based vaccines had shown promise in resected pancreatic cancer patients during early phase trials, and algenpantucel-L vaccine is currently being evaluated in adjuvant setting in a randomized trial. This review focuses on novel adjuvant therapies currently in clinical evaluation.

Original languageEnglish (US)
Pages (from-to)430-435
Number of pages6
JournalJournal of Gastrointestinal Oncology
Issue number4
StatePublished - Jan 1 2015
Externally publishedYes


  • Adjuvant therapy
  • Immunotherapy
  • Pancreatic cancer
  • Vaccines

ASJC Scopus subject areas

  • Oncology
  • Gastroenterology


Dive into the research topics of 'Novel adjuvant therapies for pancreatic adenocarcinoma'. Together they form a unique fingerprint.

Cite this